A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

NCT07465835 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

T Cell Malignancies

Interventions

DRUG: ELA026

Sponsor

Electra Therapeutics Inc.